Highest-materiality recent filing
Ernexa Therapeutics posts updated investor presentation; no specific details provided
Updated presentation posted on July 2, 2026, replacing the February 26, 2026 version.
Ernexa Therapeutics shareholders elect directors, ratify auditor, approve 2026 equity plan
All five director nominees elected: Bristol, Cicala, Luther, Ratner, Wexler; broker non-votes 161,165.
SVP of Finance Sandra Gurrola resigns, effective July 3, 2026
Sandra Gurrola, SVP of Finance, resigned June 22, 2026, effective July 3, 2026.
Ernexa Therapeutics effects 1-for-25 reverse stock split, effective May 4, 2026
Reverse stock split at 1-for-25 ratio; trading on split-adjusted basis began at market open on May 4, 2026.
Received Nasdaq notice on March 18, 2026 for failure to maintain $1.00 minimum bid price for 30 consecutive business days.
Ernexa Therapeutics posts updated investor presentation on February 26, 2026
Updated presentation replaces the December 11, 2025 version; available on company website.
Ernexa Therapeutics prices $10.5M public offering of 21M shares and warrants
Offering of 21M shares of common stock (or equivalents) and warrants to buy 21M shares at $0.50 per unit.
Ernexa Therapeutics posts new investor presentation; details not disclosed in filing
Company made a December 2025 investor presentation available via 8-K and its website.
Ernexa Therapeutics dismisses Grant Thornton, appoints Haskell & White as auditor
Dismissal of Grant Thornton effective June 30, 2025; appointment of Haskell & White effective July 1, 2025, approved by Audit Committee.
Ernexa Therapeutics effects 1-for-15 reverse stock split effective June 12, 2025
Certificate of amendment filed with Delaware Secretary of State on June 10, 2025.
Second closing on June 9, 2025: issued 47.7M shares and 9.3M pre-funded warrants for ~$6.0M gross proceeds.
Ernexa shareholders approve reverse stock split, share increase to 150M, and written consent
Elected all five director nominees: James Bristol, Peter Cicala, Sanjeev Luther, Elena Ratner, William Wexler.
Eterna Therapeutics raises up to $7.3M in private placement; resets annual meeting to June 2
Initial closing on April 2: sold 9.93M shares and 509,736 pre-funded warrants for $1.1M.
Eterna Therapeutics renames to Ernexa Therapeutics Inc. effective March 26, 2025
Company changed its name from Eterna Therapeutics Inc. to Ernexa Therapeutics Inc.
Eterna Therapeutics issues $750K promissory note to insider Charles Cherington at 5% due June 2025
Issued $750,000 promissory note to Charles Cherington, who owns ~32% of ERNA shares.
Eterna Therapeutics issues $1.5M promissory note to Charles Cherington at 5%
Principal amount $1,500,000 at 5.0% annual interest, paid at maturity.
Eterna Therapeutics sets 2025 annual meeting for May 1; shareholder proposals due Feb 23
Annual meeting date: May 1, 2025; over 30 days before one-year anniversary of 2024 meeting.
Eterna receives Nasdaq delisting notice for low MVLS; board changes
Nasdaq notified Eterna on Jan 6, 2025 that MVLS was below $35M for 35 consecutive business days.
Notice received December 30, 2024: closing bid price below $1 for 30 consecutive business days.
Stockholders approved issuance of shares for September 2024 transactions at Oct 29 annual meeting.
Exclusive license in cancer, autoimmune disorders, and rare diseases; replaces Nov 2023 and prior Exacis licenses.
Eterna raises $3.9M via 12% notes; proposes debt/warrant exchange for 38.3M shares
Closed $3.9M 12.0% senior convertible note private placement; net proceeds for general corporate purposes.
On Sept 17, 2024, Nasdaq determined Eterna did not meet the extension terms to demonstrate compliance with the Minimum Stockholders' Equity Rule (stockholders' equity < $2.5M as of Dec 31, 2023).
Eterna Therapeutics sets 2024 annual meeting for Sept 27; proposal deadline Aug 29
Annual meeting scheduled for September 27, 2024.
Eterna Therapeutics receives Nasdaq delisting notice for stockholders' equity below $2.5M minimum
Stockholders' equity was $2.2M as of Dec 31, 2024, below the $2.5M minimum required by Nasdaq Listing Rule 5550(b)(1).
Eterna Therapeutics appoints Peter Cicala to Board of Directors
Appointed Feb 12, 2024, effective immediately; independent director under Nasdaq rules.
Eterna receives Nasdaq non-compliance notice over board independence; has 45 days to submit plan
Received Nasdaq notice on Jan 17, 2024 for failing majority independent board and audit committee rules under Listing Rule 5605.
Eterna raises $9.2M convertible debt, CEO resigns, Sanjeev Luther appointed
Issued $9.2M principal of 12% senior convertible notes; initial close of ~$7.8M on Dec. 15, remainder by Jan. 15, 2024.
Eterna Therapeutics issues $1.5M promissory note to Charles Cherington due Jan 8, 2024 at 6%
Principal amount $1,500,000; interest rate 6% per annum; matures January 8, 2024.
Amended & Restated Exclusive License Agreement dated Nov 14, 2023 expands Eterna's rights to include necessary know-how and multi-tier sublicensing.
Dr. James Bristol appointed to board of Eterna Therapeutics
Dr. James Bristol appointed as director effective Oct 30, 2023; term until 2024 annual meeting.
Eterna receives Nasdaq delisting notice for audit committee non-compliance; director Fiore resigns
Nasdaq notified Eterna on Oct 3, 2023 that audit committee no longer meets minimum three-member/independence requirement after Binder and Wagner resignations.
Dorothy J. Clarke appointed to all three committees of Eterna Therapeutics Board
Dorothy J. Clarke appointed to Audit Committee, Compensation Committee, and Nominating and Governance Committee.
Eterna Therapeutics appoints Dorothy J. Clarke as director effective August 28, 2023
Ms. Clarke served as VP, Health Care Compliance R&D at Johnson & Johnson until November 2022.
CEO resigns, then reappointed; board resignations trigger Nasdaq non-compliance
CEO Dr. Angel resigned Aug 4 citing board's exclusion from business dev; rescinded Aug 8, reappointed Aug 9.
Eterna Therapeutics posts August 2023 investor presentation; no material news disclosed
Item 7.01 furnished new investor presentation (Exhibit 99.1) with no specific financial results or corporate events.
Eterna Therapeutics issues $8.715M in 6% convertible notes and warrants
Aggregate principal $8,715,000, 6.0% Senior Convertible Notes due July 14, 2028; interest payable quarterly.
Eterna Therapeutics amends Factor license: adds veterinary use, $416k/mo fee from Sep 2024
Amendment expands field of use to include veterinary uses; initial term extended to 5 years if $6M paid.
Eterna Therapeutics appoints Binder and Wagner to Board; Singer and Cherington resign
Nicholas Singer and Charles Cherington resigned from Board on July 6, 2023; resignations not due to any disagreement.
Eterna Therapeutics shareholders approve all four proposals at 2023 annual meeting
Elected five directors: Cherington, Angel, Fiore, Wexler, Singer — each received >2.68M votes for, ~770K broker non-votes.
Eterna Therapeutics appoints Sandra Gurrola as PFO; CFO Jackson resigns with $207,500 severance
Andrew Jackson resigned as CFO effective May 4, 2023; receives $207,500 salary continuation for 6 months plus COBRA premiums.
Eterna Therapeutics acquires Exacis Biotherapeutics' IP assets in stock-and-contingent deal
Eterna issued 69,343 shares to Exacis at closing; shares subject to 12-month lockup.
Eterna Therapeutics secures up to $10M equity line from Lincoln Park Capital
Lincoln Park committed to buy up to $10M of common stock over 24 months at Company's discretion.
Eterna Therapeutics posts FY2022 net loss $24.6M; licenses iPSC tech to Lineage, subleases BMS space
Net loss for Q4 2022 was $4.5M ($1.24 per share); full year net loss $24.6M ($8.06 per share).
Eterna enters exclusive license with Factor for patents; prior deal terminated
Exclusive worldwide license under Factor's patents for human uses; term ends Nov 22, 2027, auto-renewed 2.5 years if Eterna receives $100M in sublicense fees.
Eterna Therapeutics CMO Dr. Roger Sidhu resigns effective Jan 31, 2023
Dr. Roger Sidhu, Chief Medical Officer, resigned on Jan 20, 2023 with effective date Jan 31, 2023.
Eterna Therapeutics transfers Nasdaq listing to Capital Market, effective Jan 11, 2023
Nasdaq Staff approved transfer from Global Market to Capital Market on Jan 9, 2023.
Eterna Therapeutics to transfer Nasdaq listing after equity shortfall; Dr. Angel appointed CEO
Stockholders' equity of $8.8M missed Nasdaq Global Market's $10M minimum; Board authorized transfer to Capital Market on Dec 29, 2022, applied Jan 2, 2023.
Eterna Therapeutics terminates San Diego office lease; consolidates R&D to Cambridge, MA
Entered lease termination agreement for 5,193 sq ft office at 10355 Science Center Drive, San Diego.
Eterna closes ~$7.7M private placement with insider participation
Closed private placement of 2,184,950 units at $3.53/unit on Dec 2, 2022, raising ~$7.7M.
On January 6, 2025, upon the recommendation of its Nominating and Corporate Governance Committee, the Board appointed Dr. Elena Ratner to the Board effective January 7, 2025.
On January 3, 2025, Dorothy Clarke submitted her resignation from the Board of Directors (the “ Board ”) of the Company, effective at 11:59 p.m. Eastern Time on January 6, 2025.
On February 12, 2024, and effective as of that date, upon the recommendation of its Nominating and Corporate Governance Committee, the Board of Directors (the “Board”) of Eterna Therapeutics Inc. (the “Company”) appointed Mr. Peter Cicala to the Board.
On December 19, 2023, Dr. Matthew Angel notified Eterna Therapeutics Inc. (the “Company”) that he was resigning from his position as the Company’s President and Chief Executive Officer, effective on December 31, 2023.
On December 19, 2023, the board of directors (the “Board”) of the Company appointed Sanjeev Luther as the Company’s President and Chief Executive Officer (and principal executive officer), which appointment will become effective on January 1, 2024,
On October 30, 2023, the Board of Directors (the “Board”) of Eterna Therapeutics Inc. (the “Company”) appointed Dr. James Bristol as a director, effective on October 30, 2023.
O n October 4, 2023 Gregory Fiore resigned from the Company’s board of directors.
On August 28, 2023, the Board of Directors (the “Board”) of Eterna Therapeutics Inc. (the “Company”) appointed Ms. Dorothy J. Clarke as a director, effective on August 28, 2023.
On August 8, 2023, Mr. Brant C. Binder and Dr. Richard W. Wagner resigned from the Board
On August 8, 2023, Mr. Brant C. Binder and Dr. Richard W. Wagner resigned from the Board
On August 4, 2023, Dr. Matthew Angel resigned from the Board and as the Company’s President and Chief Executive Officer
the Board reappointed Dr. Angel as the Company’s President and Chief Executive Officer
Max materiality 0.80 · Median 0.55 · Most common event other_material